Patient Dies After Taking Pfizer’s Drug for Blood Disorder

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders.

The death occurred on Dec. 14 after the patient experienced “serious adverse events,” including a stroke and brain bleeding, according to a statement from the European Haemophilia Consortium, a patient group. The patient was participating in an open-label extension study of Hympavzi, which is approved to treat the condition that prevents blood from clotting properly and can lead to life-threatening bleeding in muscles, joints and organs.